REMOWELL2 is designed to reduce neurological injury and inflammatory response in Patients undergoing cardiac surgery, thanks to its unique and patented cardiotomy features capable to reduce lipids and leukocytes cells coming from pericardial suction blood. Literature evidenced the efficacious filtration by REMOWELL technology of LME (Lipid Micro Emboli) in the clinical setting and the subsequent attenuation of NSE release, a known marker of neurologic injury. In addition, significantly lower concentration of cystatin C, a known biomarker of kidney function, was found in the postoperative period, suggesting a renoprotective role for LME filtration9. The Remowell filtration technology, effectively contribute to reduce inflammatory response and minimize the negative effects of cardiopulmonary bypass.